VA Research and Development LOGO

Logo for the Journal of Rehab R&D
Volume 39 Number 2, March/April 2002
Pages 273 — 286

Immunotherapy of multiple sclerosis-Current practice and future directions
Mark J. Tullman, MD; Fred D. Lublin, MD; Aaron E. Miller, MD
The Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Mount Sinai Medical Center, 5 East 98th Street, Box 1138, New York, NY 10029
Abstract — Over the past decade, multiple sclerosis (MS) has become a treatable neurological disease. This paper reviews the therapies that have been studied to treat MS and discusses various treatment approaches on the horizon. Immunosuppressive and immunomodulatory therapies have been shown to alter the long-term course of MS. Therapies are currently available for relapsing-remitting, secondary progressive, and progressive relapsing disease. Although effective, these therapies have a modest impact on reduction in relapse rate and slowing of disease progression. Much work is needed to improve upon this modest effect and hopefully obtain a cure.

Key words: disease-modifying agents, immunomodulatory, immunosuppressive, immunotherapy, multiple sclerosis, treatment.

Contents Page for Volume 39, No 5
HTML version of article
PDF version of the article